Trostberg, May 14, 2019 – At today's Annual General Meeting of AlzChem Group AG, a vertically integrated specialty chemicals supplier with a leading market position in selected niche markets, the shareholders present honored the successful business development and corporate strategy and expressed their confidence in the Management Board and Supervisory Board. All items on the agenda were resolved by a large majority in the interests of management, which included a dividend payment of EUR 0.09 per share and, among other things, a reverse stock split of 10 to 1. With this measure, the company is responding to the wish of the majority of shareholders to reduce the number of shares to a ratio commensurate with the size and value of the company and thereby increase the stock exchange price per share to a level customary on the capital market. The measure is expected to be implemented in July/August after entry in the commercial register.
In Munich, the Management Board reported to the shareholders on the successful business development both in the short fiscal year 2018/II (period from July 1 to December 31, 2018) and in the first quarter of 2019 (period from January 1 to March 31, 2019) and confirmed the forecast for the full year 2019. In addition, it discussed in detail the development in the individual segments and the further corporate strategy.
Ulli Seibel, CEO of AlzChem Group AG: “Our company continues to develop very successfully and in the desired direction. A significant contribution will also be made in the future by our own distribution of Creamino, which has been active since the beginning of the year, and the additional Creamino production capacities that will be available from the middle of the year.”
The AlzChem Group is a vertically integrated manufacturer of various chemical products based on the NCN chain. These are products with typical nitrogen-carbon-nitrogen bonding that are used in a wide variety of different industries. The company has a leading position in select niche markets. The strategic focus of growth and the main focus of its extensive research and development are on the business segment Specialty Chemicals. The company has around 1,560 employees at four sites in Germany and three other sites abroad.